Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Ark withdraws Cerepro MAA after EMA's request for further trial in malignant glioma

March 10, 2010

FDA and EMA grant orphan drug status to ImmunoGen's IMGN-901 in MCC

March 9, 2010

Nektar Therapeutics presents phase II data on NKTR-102 in platinum-resistant ovarian cancer

March 9, 2010

MDS Foundation comments on NICE's decision against Vidaza

March 9, 2010

Studies reveal activity of DZNep in multiple myeloma and acute myeloid leukemia

March 8, 2010

Cell Therapeutics' phase III Opaxio trial in ovarian cancer to continue

March 5, 2010

DSMB supports continuation phase II Doxil trial in platinum-resistant ovarian cancer

March 5, 2010

Kinex begins phase II trial of KX2-391 in bone-metastatic CRPC

March 5, 2010

SpePharm acquires rights to Savene and partners with Paladin

March 5, 2010

Ixabepilone therapy linked to tumor regression in phase II metastatic renal cell carcinoma trial

March 5, 2010

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...